ERT’s Andreas Kitzinger Receives 2021 MCC Champion Award

PHILADELPHIA – October 6, 2021 – ERT, the global clinical endpoint data collection leader, announced today that the Metrics Champion Consortium (MCC) named Andreas Kitzinger, Director of Quality Control and Process Implementation, as a 2021 MCC Champion. The MCC Champion Award recognizes select individuals who have made significant contributions to improving clinical trials’ efficiency, quality, and effectiveness.

Since 2010, Kitzinger has led ERT’s global customer success and quality teams. He brings over 15 years of experience in the life sciences industry and a commitment to improving clinical trial planning and execution, as well as developing integrated solutions to provide access to a broader team of medical and scientific industry leaders.

“It’s an honor to be recognized by the MCC alongside remarkable colleagues and leaders in the clinical trial industry,” said Kitzinger. “Looking ahead, I’m excited to continue improving and advancing how we serve customers and support clinical trial success by leveraging the science behind data capture and our integrated endpoint technology.”

Kitzinger joins MCC’s sixth class of MCC Champions Award recipients and will be featured in the October Issue of the MCC Metric Insights Newsletter.

Founded in 2006, MCC brings together clinical trial stakeholders from across the globe to collaboratively define standardized performance metrics that organizations can utilize to oversee and improve clinical trial planning and execution with the intent to drive process improvement.

About ERT

ERT (eResearch Technology) is a global market leader and innovator in clinical trial endpoint data solutions, providing clinical study teams with the powerful and accurate data and digital results required to transform clinical trials. Between 2019-2020, 70% of all FDA drug approvals came from ERT-supported studies. With nearly 50 years of clinical and therapeutic experience, ERT’s mission is to “Transform Lives by Unlocking Better Evidence.”

In 2021, ERT merged with Bioclinica to create the global leader in clinical trial endpoint technology and leading partner to pharmaceutical and biotechnology companies, providing best-in-class technology, scientific and therapeutic expertise, and digital innovation with an unrelenting focus on customer service. The combination unites Bioclinica’s expertise in imaging, eClinical software and drug safety solutions with ERT’s expertise in eCOA, cardiac safety, respiratory and wearables. The combined company has thirty-one offices in eight countries. The global pharmaceutical industry has relied on its solutions across 19,000+ clinical trials, resulting in over 870 drug approvals to date.

ERT Media Contact
Suzanne Harris
Senior Director, Corporate Brand and Marketing
[email protected]

Share